Clariant's extensive manufacturing footprint ensures quick delivery and competitive pricing, as well back-up capacity to meet the BCP (Business Continuity Planning) requirements of global players in the pharmaceutical industry. All products produced at the Cuddalore facility will meet US FDA and EU standards for use in pharmaceutical applications and will be USP <670> compliant.  The Cuddalore facility is equipped with an ISO Class 8 clean room and will implement GMPs and environmental controls with a path toward ISO 15378 certification.

"The new site will serve the Indian pharmaceutical industry with state-of-the-art desiccant products produced under the strictest quality and compliance standards, and within a secure, truly global manufacturing network," said Matthias Brommer, Head - Clariant Healthcare Packaging. "We are extremely excited that facility construction, and production plans are moving at full speed ahead, according to schedule. The production capabilities at this new facility will add significantly to our global dessicant canister production capacity during 2017."

END